Trials / Completed
CompletedNCT06273774
A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Participants With Bipolar I Disorder
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate the safety and tolerability of MK-8189 in participants with stable bipolar I disorder. There was no hypothesis testing in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8189 | Oral Tablet |
| DRUG | Placebo | Oral Tablet |
Timeline
- Start date
- 2024-04-08
- Primary completion
- 2024-08-21
- Completion
- 2024-08-21
- First posted
- 2024-02-23
- Last updated
- 2025-08-17
- Results posted
- 2025-08-17
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06273774. Inclusion in this directory is not an endorsement.